Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06294691
Other study ID # infusion time & aGVHD-002
Secondary ID
Status Not yet recruiting
Phase Phase 3
First received
Last updated
Start date March 1, 2024
Est. completion date August 31, 2026

Study information

Verified date February 2024
Source Anhui Provincial Hospital
Contact Xiaoyu Zhu, ph.D
Phone 15255456091
Email xiaoyuz@ustc.edu.cn
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To observe the effect of stem cell infusion on the development of acute graft- versus-host disease (aGVHD) in patients with nonmalignant hematologic diseases after allogeneic peripheral blood hematopoietic stem cell transplantation (allo-PBSCT)


Description:

Acute graft-versus-host disease (aGVHD) is a major complication and non-recurrent cause of death after allogeneic hematopoietic stem cell transplantation (allo-HSCT). The human biological clock uses recurring environmental cues such as light and food intake to establish 24-hour rhythmic changes in sleep, hormone secretion, metabolism, body temperature, and immune function. Current clinical aGVHD prevention strategies focus on suppression of donor lymphocyte function by drugs or immunomodulatory cells, ignoring the impact of the recipient's own functional changes on the graft. The applicant's previous retrospective cohort study found that the time of stem cell infusion severely affected the incidence of aGVHD and its severity after allogeneic peripheral blood hematopoietic stem cell transplantation (allo- PBSCT). Due to the lack of prospective clinical trial results on the effect of stem cell infusion time on the occurrence of aGVHD after allo-HSCT in the international arena, as well as the possible influence of multiple confounding factors in the aforementioned single-center retrospective study, the present study intends to randomize patients according to the time of stem cell infusion, and to observe its effect on the incidence of aGVHD, other transplant-related complications, and long-term survival after allo-PBSCT of patients with nonmalignant hematologic diseases.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 198
Est. completion date August 31, 2026
Est. primary completion date November 30, 2025
Accepts healthy volunteers No
Gender All
Age group 12 Years to 60 Years
Eligibility Inclusion Criteria: - Definite diagnosis of malignant hematologic disease before transplantation, age 12-60 years old, gender is not limited, race is not limited; - Patients who are proposed to receive allo-PBSCT for the first time; - Eastern Cooperative Oncology Group (ECOG) score 0-2; - No serious organ failure and active infection; - Voluntary open randomized controlled study to observe whether the time of stem cell infusion affects the occurrence of aGVHD after transplantation; - Each subject must sign an informed consent form (ICF) indicating that he/ she understands the purpose and procedures of the study and is willing to participate in the study; in view of the patient's condition, if the patient's own signature is not conducive to the treatment of his/her condition, the ICF will be signed by the legal representative. Exclusion Criteria: - Those with severe organ dysfunction or disease, such as severe disease and dysfunction of the heart, liver, kidneys and pancreas; - Pregnant patients; - Patients and/or authorized family members who refuse to undergo an open randomized controlled study to observe whether the time of stem cell infusion affects the occurrence of aGVHD after transplantation; - Any life-threatening disease, physical condition, or organ system dysfunction that, in the opinion of the investigator, may compromise patient safety and put the results of the study at unnecessary risk; drug-dependent individuals; patients with uncontrolled psychiatric disorders; and individuals with cognitive dysfunction; - Participants in other clinical studies that may affect aGVHD within 3 months; - Those whom the investigator considers unsuitable for enrollment (e.g., those who anticipate that patients will not be able to adhere to the examination and treatment due to financial and other issues).

Study Design


Intervention

Procedure:
Time of stem cell infusion
Randomization of patients according to the time of stem cell infusion

Locations

Country Name City State
China The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital) Hefei Anhui

Sponsors (1)

Lead Sponsor Collaborator
Anhui Provincial Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary The cumulative incidence of grade III to IV aGVHD The primary endpoint of the study will be the development of aGVHD in the first 100 days post-transplant. aGVHD was graded according to the Mount Sinai Acute GVHD International Consortium criteria. 100 days
Secondary The cumulative incidence of grade II to IV aGVHD The cumulative incidence of grade II to IV aGVHD in the first 100 days post-transplant. aGVHD was graded according to the Mount Sinai Acute GVHD International Consortium criteria. 100 days
Secondary The cumulative incidence of neutrophil engraftment at 28 days after transplantation neutrophil engraftment time was defined as the first of three consecutive days during which the neutrophil count was at least 0.5×10^9/L. 28 days
Secondary The cumulative incidence of platelet recovery at 100 days after transplantation Platelet recovery is defined as independence from platelet transfusion for at least 7 days with a platelet count of more than = 100 × 10^9/L. 100 days
Secondary The cumulative incidence of transplant-related mortality at 180 days after transplantation The cumulative incidence of transplant-related mortality at 180 days after transplantation. 180 days
Secondary The cumulative incidence of transplant-related mortality at 360 days after transplantation The cumulative incidence of transplant-related mortality at 360 days after transplantation. 1360 days
Secondary The cumulative incidence of chronic GVHD at 360 days after transplantation The severity of chronic GVHD was graded according to the 2014 NIH criteria. 360 days
Secondary The probability of GVHD-free, relapse-free survival(GRFS) The composite endpoint of GRFS was defined as the first events occurring after transplantation among Grade III to IV aGVHD, moderate to severe cGVHD, relapse, or death for any reason. 360 days
Secondary The probability of disease-free survival(DFS) The DFS was defined as the interval between transplantation and disease recurrence, death or the last follow-up date, whichever occurred first. 360 days
Secondary The probability of overall survival(OS) The OS was determined to be the time from the first day of transplantation until death from any cause or the last follow-up date. 360 days
See also
  Status Clinical Trial Phase
Recruiting NCT02241018 - MSCs Combined With CD25 Monoclonal Antibody and Calcineurin Inhibitors for Treatment of Steroid-resistant aGVHD Phase 2/Phase 3
Completed NCT04539470 - Study to Evaluate the Safety and Pharmacokinetics of Efmarodocokin Alfa in Combination With Standard of Care in Participants Undergoing Allogeneic Hematopoietic Stem Cell Transplantation Phase 1
Terminated NCT02245412 - A Phase 2A Study of ALXN1007 in Participants With Newly Diagnosed Acute Lower Gastrointestinal Graft-Versus-Host Disease Phase 2
Recruiting NCT02659657 - Prophylaxis Roles of IL-2 Treatment on GVHD After Transplantation Phase 2
Completed NCT03497273 - Safety of Itacitinib in Combination With Corticosteroids for Treatment of Steroid-Naive Acute Graft-Versus-Host Disease in Japanese Subjects Phase 1
Completed NCT05825833 - Infliximab Efficacy in Relation to Therapeutic Drug Monitoring and Serum TNFα Levels in Pediatric HSCT
Not yet recruiting NCT06294678 - Effect of Stem Cell Infusion Time on aGVHD in Patients With Hematological Malignancies Phase 3
Recruiting NCT04285424 - FMT for Steroid Resistant Gut Acute GVHD Early Phase 1
Terminated NCT01903473 - Donor Regulatory T Cells Infusion in Patients With Chronic Graft-versus-host Disease (GVHD) Phase 2
Recruiting NCT02044185 - Clinical Implications of HMGB1 in Patients Treated With Chemotherapy or Hematopoietic Stem Cell Transplantation N/A
Recruiting NCT01765634 - Mesenchymal Stem Cells for Treatment of Refractory Acute Graft-versus-host Disease Phase 2
Terminated NCT00282503 - Extracorporeal Photoimmune Therapy With UVADEX for the Treatment of Acute Graft Versus-Host Disease Phase 3
Recruiting NCT01521039 - Assessment of MicroRNA Expression in Acute Graft-versus-Host Disease
Terminated NCT03721965 - Safety and Efficacy of Itacitinib in Combination With Corticosteroids for Treatment of Graft-Versus-Host Disease in Pediatric Subjects Phase 1/Phase 2
Not yet recruiting NCT04971551 - A Study of Jaktinib for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease. Phase 2
Completed NCT02743351 - Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic Malignancies Phase 1/Phase 2
Active, not recruiting NCT06394895 - Donor Neutrophil Subsets to Predict the Risk of aGVHD
Terminated NCT05673876 - A Study to Assess the Safety and Pharmacokinetics of GDC-8264 in Combination With Standard of Care in Participants With Acute Graft-Versus-Host Disease (aGVHD) Phase 1
Recruiting NCT02611180 - Dendritic Cells in Patients With Acute or Chronic Skin Graft Versus Host Disease